Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
for diabetes and Zepbound for weight loss, both comprising the same ingredient, tirzepatide, a dual GIP/GLP-1 RA. Despite facing strong competition from Novo Nordisk 's NVO semaglutide medicines, Ozempic for diabetes and Wegovy for obesity, Lilly's drugs have witnessed strong uptake since launch, becoming its key top-line drivers. In the first nine months of 2025, Mounjaro and Zepbound generated combined sales of $24.8 billion, accounting for 54% of Eli Lilly's total revenues. However, the pharma giant is facing mounting competitive pressure as several smaller biotech players are advancing rapidly in the obesity arena, attracted by the sizeable and still underpenetrated market opportunity. Earlier this week, Structure Therapeutics GPCR reported positive top-line data from the ACCESS clinical program of its investigational candidate, aleniglipron, for treating obesity. In the core 36-week phase IIb ACCESS study, GPCR's aleniglipron met its primary and all key secondary endpoints,
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Bank of America Corporation from $1,286.00 to $1,268.00. They now have a "buy" rating on the stock.MarketBeat
- Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $951.00 to $1,145.00. They now have a "buy" rating on the stock.MarketBeat
- Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/8/25 - Form 3
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- LLY's page on the SEC website